

Exploring Local Literature Bias: A Critical Evaluation of Iranian Trials on the Efficacy of Psychotherapy for Chronic Pain

Ali Zia-Tohidi^{1*}, Zahra Shamshiri¹, Fatemeh Askari¹, Manijeh Firoozi²

¹ Faculty of Management and Accounting, Farabi Campus, University of Tehran, Qom, Iran

² Department of Psychology, Faculty of Psychology and Education, University of Tehran, Tehran, Iran

*Corresponding Author: Ali Zia-Tohidi, Ph.D., Faculty of Management and Accounting, Farabi Campus, University of Tehran, Qom, Iran. Tel: + 98-9109615720, Email: towahidi@ut.ac.ir

Received January 16, 2023; Accepted February 5, 2023; Online Published March 15, 2023

Abstract

Background: Seeking local evidence on treatment efficacy is necessary if cultural factors are involved, as in psychotherapy for Chronic Pain (CP). Yet, local evidence is known to be prone to bias, making it difficult to reach reliable conclusions.

Objectives: This study aimed to critically evaluate our local evidence on the efficacy of psychotherapy on quality of life and disability in CP. It has been elaborated that, with some requirements, common meta-analytic tools can be utilized to detect and correct local evidence bias.

Methods: The protocol was registered on PROSPERO, Record [deleted for blind review]. Elmet, Pubmed, and ProQuest were searched for randomized trials. A multilevel meta-analysis was used to capture the hierarchical structure of the data, and robust variance estimation was used for inference. Several moderation analyses were conducted, and publication and other related sources of bias were examined.

Results: Forty-two trials were initially included. Six were excluded before the analysis due to serious reporting problems undermining their validity. The *SMD* from 185 effect sizes was 1.08 [.87, 1.3]. The funnel plot showed a strong bias. The bias-corrected estimate from a regression-based method was 0.45 [0.04, 0.87], and from the trim-and-fill was 0.75 [0.48, 1.0].

Conclusion: While our original estimate was large, the corrected estimation showed a medium effect, fairly comparable to the international estimates. Current evidence on different sources of bias in our literature suggests low quality and questionable research practice as the first suspects for our local evidence bias.

Keywords: Pain, Quality of Life, Behavioral Medicine, Systematic Review, Meta-analysis, Iran

1. Background

Before the 1960s, Chronic pain (CP) was mostly regarded as purely physiological.¹ A large body of evidence has since emerged leading to a consensus of experts on a biopsychosocial perspective.² This shift has put psychological interventions at the core of CP management, with hundreds of Randomized Clinical Trials (RCTs) supporting these interventions.³⁻⁵

However, current empirical evidence on psychotherapy for CP is mostly from American and European studies, which may not be generalizable to culturally distinct populations (e.g. Middle Eastern societies such as Iran), especially considering the psychosocial aspects of CP^{6,7} and the culturally sensitive nature of psychotherapy.^{8,9} This highlights the need for local evidence on efficacy.

In Iran, dozens of RCTs have evaluated the efficacy of psychological interventions in CP. Within the last five years, several meta-analyses had summarized this evidence,¹⁰⁻¹² reporting effect sizes that were far larger

than non-Iranian estimates.³⁻⁵ On the surface, this may seem promising, but we doubt whether such large differences are attributable to cultural factors.

1.1. Is the Difference Genuine or a Function of Bias?

The difference between the estimates from Iranian and non-Iranian studies can be genuine. Iranian CP patients may benefit more from psychological interventions, due to some characteristics in patients, therapists, and/or environment. However, there is an alternative explanation: the difference may be a function of bias in the estimates of the efficacy the treatment.

While it is tempting to believe that psychotherapy is as effective as our local estimates indicate, we have enough reason to be skeptical. The pattern of local evidence producing more favorable results is not limited to this topic and not to Iranian studies. Several investigations on different health-related topics suggest that compared to

international evidence, studies from some countries tend to produce larger effects and higher rates of significant results.^{13–16} Generally, trials conducted in less-developed countries seem to produce more favorable results.¹⁷

It can be mentioned that, it is not easy to determine whether the difference between local and international estimates is real or induced by biased estimates on one side. Indeed, unless we have multinational RCTs, we may not be able to directly address such a question, as controlling for confounding factors is very difficult, if not impossible. However, we can explore different sources of bias that can lead to such differences.

1.2. Methods to Examine the Presence of Bias in Local Evidence

To explore bias, we can use internal and external information. External information comes from the outside of the studies under investigation. For instance, if we have evidence that the acceptance of a manuscript in Iranian journals is more affected by the reported effect size or *p*-value, we may suspect that publication bias has inflated the effect size from Iranian trials, leading to a difference between their effect size and the international estimates. Internal information, on the other hand, comes from the collective patterns among the studies under investigation, such as using funnel plot to explore publication bias.

Collecting external information on local evidence bias in a given topic requires familiarity with such potential sources of bias. Current literature suggests several sources. First, publication bias may be greater in some countries—i.e., publishing a non-significant result may be more difficult in some countries.¹³ Second, research quality is not similar across countries,¹⁵ and lower quality is shown to be associated with inflated effect size.¹⁸ Finally, while questionable research practice (e.g., *p*-hacking) and misconduct (i.e., data falsification and data fabrication) are worldwide issues, they may not be equally common across countries. There is reliable evidence that the rate for such behaviors is higher in low- and middle-income countries.¹⁹

Regarding the internal information, it is well known that publication bias can be evaluated in a meta-analysis. A common tool for assessing and visualizing publication bias is the funnel plot. The funnel plot is a simple scatter plot, in which the effect size is plotted against a measure of precision (such as sample size or other related measures).²⁰ If publication bias exists, we expect an asymmetry in the plot, because small trials tend to get published only if they report significant results while large trials are likely to get published regardless of the statistical significance of their results (for an example, see Figure 2 in the Results section).

What is less known is that misconduct and questionable research practice can also cause asymmetry in the funnel plot.²¹ Assume that for a given treatment, the true effect

size is $SMD = 0.5$. In some small RCTs with an *SMD* estimate of around 0.5, the statistical tests may not reach significance. A researcher may feel tempted to fraudulently change the data to elevate the effect size and get a significant result. Another researcher may exclude some valid cases to reach statistical significance. These behaviors lead to a systematic change in the observed effect sizes from small trials and produce an asymmetry in the funnel plot.

Furthermore, study quality can also cause asymmetry in the funnel plot. Larger studies usually have higher quality, and high-quality trials tend to report lower effect sizes; putting differently, low-quality studies tend to have higher effect sizes due to biased estimation.²¹ This leads to an asymmetry in the plot.

Besides using the funnel plot (or other similar methods), there is a second source of internal evidence: When we carefully review the studies under investigation, we may find some evidence of problematic quality or misconduct/questionable research practice. Also, some moderation analyses can provide further evidence. For instance, if dissertation projects, which are published in some databases regardless of the significance of their results, show smaller effect sizes than other studies, it may indicate the presence of publication bias.

1.3. Obtaining Sensible Estimates from Biased Evidence

As bias is a systematic deviation in the estimate, it can be corrected, if we know its direction and magnitude. The methods that have been devised to evaluate publication bias (e.g., the funnel plot or Egger's regression) can provide an estimate of the direction and magnitude of bias. Although they are commonly assumed to assess merely publication bias, they indeed assess funnel plot asymmetry, whether it is caused by publication bias, questionable research practice, misconduct, or lower quality of small studies. The corresponding corrections also provide less biased estimates, regardless of the source of bias.

While useful, these methods have a requirement. They are based on the relation between sample size (or other related concepts) and effect size. To capture such a relationship, we need to have sufficient variability in the study size, and we need some trials with fairly large samples; otherwise, the logic behind these methods does not stand. In such a situation, a meta-analyst may use such methods and falsely assume that the bias is corrected. Therefore, in our previous meta-analyses on similar topics, we did not perform such analyses.^[references were deleted for blind review] However, if we find a context where we can apply such methods, we may be able to provide a reliable answer to whether psychotherapy for Iranian CP patients is as effective as the previous meta-analytic estimates suggest,^{10–12,22} or that those estimates were partly functions of local evidence bias.

1.4. The Current Study

The aim of the present study was to critically evaluate the evidence on the efficacy of psychological interventions for improving quality of life and reducing disability in Iranian adults with CP. The choice of these outcomes is based on several points: (a) we have large trials that have evaluated these outcomes, allowing proper evaluation and correction for bias, (b) there are a large number of trials that have reported outcomes on these variables, and (c) these outcomes have not yet been examined systematically. We will provide a corrected estimate for the treatment efficacy. Applying the new advanced meta-analytic methods, we will decompose the within- and between-study variability to evaluate how different sources of variance have contributed to the total variance. Finally, we will provide some estimates on pre-posttest improvement in experimental and control conditions, which is not meant to provide evidence of the efficacy but to provide some information for practitioners regarding the expected improvement.

2. Methods

This study was a systematic review and a meta-analysis reporting the following PRISMA guidelines.

2.1. Protocol and Registration

The protocol for this review was registered on PROSPERO, Record [deleted for blind review].²³ However, two changes were made. First, we decided not to perform a risk of bias assessment. We came to this decision after further evaluation of our previous assessments for similar topics.¹⁰⁻¹² On one hand, previous assessments suggested minimal variability across trials; almost all trials had an overall low or unclear risk of bias. Due to the lack of variability, reliably exploring the relation between study quality and effect size was not possible. On the other hand, the descriptive purpose of such an assessment was already achieved by previous assessments.^{11,12,24} Considering it all together, it seemed that such an assessment is of little use and is likely a waste of resources. Second, we added three moderators: scale type (QoL vs. disability), scale domain (e.g., physical, psychological), and follow-up duration. To note, these additional variables were specified before data analysis—i.e., they were not post hoc analyses.

2.2. Eligibility Criteria

2.2.1. Participants and Settings

Iranian adults (age > 16) with a diagnosis of any CP condition were eligible, except for pain related to cancer or Multiple Sclerosis (MS). No setting restriction was considered.

2.2.2. Interventions

Psychological interventions were eligible, from any type

and in any delivery format (e.g., individual or group therapy). We excluded interventions with merely medical education (e.g., postural training for back pain) or substantial physical elements (e.g., yoga), as there may be some doubt about whether these should be classified as psychological interventions. To reduce heterogeneity, we also excluded brief interventions that were delivered in less than four sessions.

2.2.3. Type of Control

Active or nonactive control groups were eligible.

2.2.4. Outcome Measures

All measures of quality of life or disability were eligible.

2.2.5. Study Design

Randomized trials published in peer-reviewed journals, theses/dissertations, and full-text conference articles were included.

2.3. Information Sources, Search Strategy, and Study Selection

On May 2021, we searched Elm-Net, PubMed, and ProQuest for eligible records. Different combinations of the following words (or their Persian synonyms) were used: pain, fibromyalgia, irritable bowel syndrome, disability, and quality of life. For Pubmed and ProQuest, some terms were added to restrict the search to Iranian studies: Iran, Iranian, Persian, and Farsi. We also searched the citations from previous meta-analyses with related topics.^{10-12,22} The titles and abstracts were screened by one reviewer. The full-text assessments were done by two independent reviewers. Among the 67 reports, their initial decisions were consistent in 58 records (86%, Cohen's kappa = .49). The disagreements were resolved through discussion.

2.4. Data Preparation and Synthesis Methods

2.4.1. Calculating Within-study Effect Sizes

Three types of Standardized Mean Difference (SMD) were calculated for each outcome: the between-group post-test difference and the within-group pre-posttest differences in experimental and control groups. Whenever possible, the effect size was calculated from the results of the analysis of covariance, which provides a more precise estimate of the intervention effect.²⁵ If data on subscales were available, they were preferred over the overall scale. All the effect sizes were corrected for small sample bias.²⁶

2.4.2. Data Screening

The previous investigations on related topics in our literature suggest the necessity of careful examination of included RCTs for inconsistency and practically impossible results.¹⁰⁻¹² In this study, we first screened the




Figure 1. PRISMA Diagram for Search and Screening Processes

Table 1. Characteristics of the Included Studies

Study	Pain type	Intervention (format, sessions)	Measure	N	Num. of ESs
Tabatabaee 2014 ⁵⁴	IBS	metacognitive therapy (gp, 8)	SF-36	21	8
Zomorodi 2013 ⁵⁵	IBS	CBT (gp, 8), MBSR (gp, 8)	IBS-QoL-34	36	4
Sadeghi 2015 ⁵⁶	LBP	Emotion regulation training (gp, 8), Coping skills training (gp, 8)	SF-36	60	16
Tavakoli 2019 ⁵⁷	NCCP	ACT (gp, 8)	SF-36	40	4
Firoozi 2020 ⁵⁸	LBP	positive thinking-based CBT (cellphone, 30 days)	WHOQL-26	62	4
Rezaie 2014 ⁵⁹	RA	emotion-focused CBT (gp, 8), schema therapy (gp, 8)	QoL-RA-8	30	4
Masumian 2013 ⁶⁰	LBP	MBSR (gp, 8)	SF-36	18	8
Ghotbinejad 2019 ⁴²	CP	positive psychotherapy (gp, 15), psychodrama (gp, 10)	SF-36	45	4
Haghighayegh 2010 ⁶¹	IBS	CBT (gp, 8)	IBS-QoL-34	24	2
Salarian 2020 ⁴³	CP	mindfulness (gp, 8)	WHOQL-26	26	1
Abazari 2016 ⁶²	LBP	hypnotherapy (ind, 6)	RMQ-24	28	1
Sadeghi 2020 ³⁵	RA	ACT (gp, 8)	ODI-10(v2.0)	40	1
Parhizgar 2020 ⁶³	IBS	mindfulness integrated CBT (gp, 8)	IBS-QoL-34	24	1
Shafiee Fard 2015 ³⁶	CP	CBT (gp, 12)	SF-36	30	8
Naddafnia 2019 ⁴¹	IBS	CBT (gp, 12)	IBS-QoL-34	23	16
Farokhzadian 2019 ⁶⁴	IBS	ACT (gp, 8)	IBS-QoL-34	30	1
Kamkar 2011 ⁶⁵	IBS	stress management CBT (gp, 8)	IBS-QoL-34	42	16
Haghaegh 2012 ⁴⁰	IBS	emotion focused therapy (gp, 8), DBT (gp, 8)	IBS-QoL-34	60	4
Mohamadi 2017 ⁶⁶	IBS	DBT (gp, 8)	IBS-QoL-34	30	1
Azizi 2018 ⁶⁷	IBS	mindfulness (gp, 8)	IBS-QoL-34	30	1
Dabbaghi 2015 ⁶⁸	IBS	MBSR (gp, 8)	IBS-QoL-34	12	1
Solati 2009 ⁶⁹	IBS	CBT (gp, 8), life style education (gp, 8), relaxation (gp, 8)	IBS-QoL-34	64	6
Pashang 2019 ⁷⁰	IBS	metacognitive therapy (gp, 8), ACT (gp, 8)	SF-36	45	4
Kheirabadi 2010 ⁷¹	IBS	Coping skills training (gp, 8)	IBS-QoL-34	46	1
Shojaei 2017 ⁷²	LBP	Multidisciplinary (gp, 4)	QDS-20	125	1
Tavafian 2011 ^{45,52,53}	LBP	Multidisciplinary (gp, 5)	SF-36, RMQ-24, QDS-20	197	60
Chamani 2019 ⁷³	IBS	CBT (gp, 10)	WHOQL-26	30	1
Anvari 2012 ⁷⁴	CP	ACT (gp, 8)	PDI-7	17	2
N. Vakili 2009 ⁷⁵	LBP	CBT (gp, 8)	SF-36	24	2
Irandoost 2014 ⁴⁴	LBP	ACT (unclear, 8)	SF-36	40	2
Rezaeian 2014 ⁷⁶	PP	ACT (gp, 8)	PDI-7	22	2
Dadollahi 2016 ⁷⁷	IBS	MBSR (gp, 9)	IBS-QoL-34	20	2
Fouladi 2018 ⁷⁸	IBS	CBT (ind, 8)	IBS-QoL-34	32	2
Jafari 2020 ³⁴	CP	MBCT (gp, 8)	WHOQL-26	30	1
Mansoori 2020 ⁷⁹	LBP	ACT (gp, 8)	WHOQL-26	20	3
T. Vakili 2020 ⁸⁰	IBS	Reality therapy (gp, 8)	WHOQL-26	30	4
Soltanian 2016 ⁸¹	RA	CBT (gp, 8)	WHOQL-26	20	4
Ayoughi 2019 ⁸²	RA	stress inoculation training (gp, 10)	SF-36	30	8
Boloursaz 2017 ⁸³	FS	Islamic-based coping strategy training (gp, 10)	WHOQL-26	30	4
Pourmohseni 2017 ³⁷	IBS	MBCT (gp, 8)	SF-36	40	7
Mahdipoor 2012 ³³	IBS	mixed (gp, 12)	WHOQL-26	30	2
Esmailpoor 2017 ³⁸	IBS	Emotional Intelligence Training (gp, 12)	WHOQL-26	36	1

ES = effect size; IBS = irritable bowel syndrome; LBP = low back pain; NCCP = noncardiac chest pain; RA = rheumatoid arthritis; CP = chronic pain (general); PP = pelvic pain; FS = fibromyalgia syndrome; CBT = cognitive-behavioral therapy; MBSR = mindfulness-based stress reduction; ACT = acceptance and commitment therapy; DBT = dialectical behavioral therapy; MBCT = mindfulness-based cognitive therapy; SF-36 = Short Form Health Survey; IBS-QoL-34 = Irritable Bowel Syndrome–Quality of Life; WHOQL-26 = World Health Organization Quality of Life; QoL-RA = Quality of Life–Rheumatoid Arthritis; RMQ-24 = Roland–Moris Disability Questionnaire; QDS-20 = Quebec Disability Scale; PDI-7 = Pain Disability Inventory.

data for such cases. Note that this procedure was not an exploration of outliers or influential cases, which is usually performed after initial analysis. We in fact excluded these studies as such results are likely due to some errors in their reports. For each study that was excluded, we explained the reason.

2.4.3. Synthesis Method

For data synthesis, a five-level meta-analytic model was implemented. Effect sizes for different measurement occasions (i.e., the posttests and follow-ups; Level 1) were nested within outcome measures (e.g., subscales of SF-36; Level 2), nested within treatment comparison (for




Figure 2. Forest Plot of the Standardized Mean Difference Between Psychological Interventions and Treatment as Usual On Quality of Life/Disability

trials with more than one experimental group; Level 3), and nested within studies (Level 4). The fifth level was, of course, the overall estimate of the effect size. The Restricted Maximum Likelihood method (REML) was used for estimating the true variance components,²⁷ and the profile likelihood method was used for calculating its confidence intervals.²⁸ As the multilevel model does not account for the dependency at the lowest level of our analysis, i.e., the sampling variance, we used the Robust Variance Estimation (RVE) method for inference.²⁹ While more complicated, this multilevel approach provides several advantages: (a) it allows us to decompose the true variance across levels (e.g., to calculate the amount of variance due to between-study variability and between-outcome variability), (b) it allows us to model the whole data simultaneously, which leads to higher statistical power, and (c) it facilitates more flexible moderation analysis using moderators at different levels (e.g., study related or outcome related characteristics).

2.4.4. Additional Analyses

Seven potential moderators were investigated in the present study: pain type (musculoskeletal vs. IBS), intervention type, researcher's education, publication type (dissertation or not), measurement type (i.e., QoL vs. disability measure), measurement domain (i.e., psychological, physical), and length of follow-up period. As the intervention types are numerous, they were classified into five main categories: cognitive behavioral, mindfulness-based, coping skills training, multidisciplinary interventions, and other approaches. If needed, we checked the intervention protocol for accurate classification.

2.4.5. Exploring Publication and Other Related Sources Bias

To investigate publication and other related sources of bias and to provide corrected estimates on the treatment efficacy, we used two methods. First, we used a recently-developed extension of the regression test, which includes

Table 2. The Moderating Effect of Pain-, Intervention-, and Measurement-Related Factors and Follow-Up Duration

Moderator	n. ESs	SMD	95% CI	Test for moderator
Pain type				$F(1, 32) = 0.00, P = 0.962, R^2 = 0$
Musculoskeletal	130	1.08	0.77, 1.39	
IBS	55	1.09	0.77, 1.41	
Intervention type				$F(4, 29) = 20.9, P < 0.001, R^2 = .01$
CBT	40	0.87	0.51, 1.24	
Coping strategy training	29	1.01	0.38, 1.65	
Mindfulness-based	41	1.36	0.93, 1.78	
Multidisciplinary	61	0.46	0.44, 0.49	
Others	14	1.13	0.93, 1.32	
Researcher's education				$F(2, 31) = 0.2, P = 0.788, R^2 = 0$
PhD	111	0.99	0.62, 1.37	
MA	66	1.14	0.82, 1.45	
Unclear	8	1.19	0.60, 1.78	
Publication Type				$F(1, 30) = 0.02, P = 0.896, R^2 = 0$
Thesis (or extracted from thesis)	74	1.12	0.79, 1.45	
Journal article	104	1.09	0.77, 1.42	
Type of measurement				$F(1, 32) = 26.6, P < 0.001, R^2 = 0$
Quality of Life	167	1.09	0.87, 1.32	
Disability	18	1.02	0.80, 1.24	
Measurement domain				$F(4, 29) = 2.4, P = 0.074, R^2 = 0$
General	38	1.17	0.86, 1.48	
Physical	65	0.96	0.62, 1.29	
Psychological	69	1.04	0.65, 1.44	
Social	9	1.23	0.87, 1.59	
Environmental	4	1.03	0.53, 1.53	
Follow-up duration (month)	185			$F(1, 32) = 351.4, P < 0.001, R^2 = 0, B = 0.003 [0.0028, 0.0034]$

The tests for moderation are based on robust variance estimation. As the models are multilevel models, the R^2 is in fact pseudo- R^2 , which extends the logic to the multilevel model framework

the inverse of *effective sample size* as a moderator in a multilevel meta-regression.²⁰ The test for the slope of the moderator examines the presence of bias, and the intercept provides a corrected estimate of treatment efficacy. It is based on the premise that when the lack of precision is associated with higher effect sizes, the predicted value at perfect precision (i.e., when the inverse of the effective sample size is zero—the intercept) is a corrected estimate. Second, we aggregated the effect sizes within each study, and then generated a standard funnel plot, along with a trim-and-fill method to correct bias.³⁰

2.4.6. Statistical Software

All analyses were conducted in R using the package “Metafor,”³¹ except for calculating *SMD* from analysis of covariance, which was made using package “compute.es”.³²

3. Results

The initial search yielded 731 records. Twelve further records were found from other sources. Of these records, 42 RCTs met our criteria, comparing 50 experimental groups to a control condition (Figure 1). Except for two, the control condition was Treatment As Usual (TAU). Overall, 225 between-group effect sizes were extracted. The most common pain type was IBS ($n = 21, 50\%$), followed by LBP ($n = 9, 21\%$). The most common intervention was CBT ($n = 9, 18\%$), followed by ACT ($n = 8, 16\%$). The total sample was 1639. A summary of the characteristics of included studies is provided in Table 1.

3.1. Initial Data Screening

The initial screening revealed three studies with *SMDs* higher than 5,³³⁻³⁵ which is probably due to some errors in their reports, because an average improvement of more than 5 *SDs* is not practically possible. Another study reported unusually different effect sizes across SF-36 subscales, with the *SMDs* ranging from -1.34 to 5.92,³⁶ indicating some errors in the report, as it is not practically possible to have an *SMD* of 5.92 in one outcome and an *SMD* of -1.34 in another highly related outcome. Another study had seven effect sizes, consistently very large, ranging from 2.71 to 4.77.³⁷ Finally, another study reported pretest mean scores of 61.27 and 58.38 on the Beck Anxiety Inventory,³⁸ which is an indication of serious problems in the report, knowing that the maximum score on the Beck scale is 63 and the average score among the clinically anxious population is about 24.³⁹ These six studies were excluded from further analysis. Note that excluding these studies was not because of them being outliers, but rather because of strong evidence of some errors in the reports that make the extracted effect sizes very likely invalid.

3.2. Psychological Interventions vs. Treatment As Usual

The overall *SMD* across 185 effect sizes was 1.08 [0.87, 1.30]. The total true variance across all levels was $\sigma^2_{\text{total}} = 0.34, I^2_{\text{total}} = 87\%$. To provide an easily readable forest plot, we calculated one aggregated effect size per study and used these to create the plot (Figure 2).

Decomposing the true variance showed that the majority of the variance is at the study level, $\sigma^2_{\text{between-study}} = 0.29$ [0.0, 0.58], $I^2_{\text{between-study}} = 76\%$, and the variance due to within-study levels was fairly small, $\sigma^2_{\text{between-group}} = 0.04$ [0.0, 0.38], $I^2_{\text{between-group}} = 10\%$; $\sigma^2_{\text{between-outcome}} = 0.01$ [0.0, 0.04], $I^2_{\text{between-outcome}} = 1\%$; $\sigma^2_{\text{between-timepoint}} = 0.0$ [0.0, 0.01]; $I^2_{\text{between-timepoint}} = 0\%$. The results of seven moderation analyses have been presented in Table 2. The influence of the moderators were nonsignificant (publication type, measurement domain, and researcher's education), negligible (follow-up duration), or difficult to interpret (intervention type; see Discussion).

3.3. Publication and other Sources of Bias

To examine publication and other related sources of bias, the inverse of the effective sample size was included as a moderator in a multilevel meta-regression (Figure 3, Panel

a). The test for the slope was significant, $F(1, 32) = 8.8$, $p = .006$, indicating the presence of bias. The intercept, a corrected estimate of treatment efficacy, was 0.45 [0.04, 0.87], which is much smaller than our original estimate. We also generated a funnel plot, based on the aggregated SMDs for each study (Figure 3, Panel b). The asymmetry of the observed SMDs (i.e., the black dots) was clear. Using the trim-and-fill method, 11 studies were imputed at the left side (the white dots in Figure 3, Panel b), reducing the SMD to 0.75 [0.48, 1.0]. While this is noticeably lower than our original estimate, it is higher than the corrected estimate from the meta-regression model.

3.4. Pre-posttest Improvement in Psychological Interventions

The pooled pre-posttest Standardized Mean Change (SMC) from 214 effect sizes only including experimental groups was 1.00 [0.79, 1.22]. The total true variance was $\sigma^2_{\text{total}} = 0.43$, $I^2 = 95\%$.




Figure 3. Regression and Funnel Plots Depicting the Presence of Bias

Table 3. Direct Contrasts Among Different Psychotherapeutic Approaches

Study	Contrast	SMD	95% CI
Zomorodi 2013	CBT – MBSR	-0.78	-1.06, -0.5
Naddafnia 2019	CBT – spiritual therapy	0.54	0.31, 0.76
Solati Dehkordi 2009	CBT – lifestyle education	-0.03	-0.23, 0.17
	CBT – relaxation training	-0.13	-0.33, 0.07
	Relaxation – lifestyle education	0.1	-0.1, 0.29
Rezaee 2014	Emotion-focused CBT – schema therapy	0.00	-0.31, 0.31
Pashang 2019	Metacognitive therapy – ACT	0.45	0.23, 0.66 ^(a)
Ghotbinejad 2019	Positive psychotherapy – psychodrama	-0.03	-0.24, 0.18
Sadeghi Mazidi 2015	Emotion regulation – coping skills training	0.42	0.28, 0.55

The SMDs are unweighted aggregate estimates from each study, and the confidence intervals are calculated based on an intercorrelation of 0.6 among the effect sizes. However, repeating the analysis based on intercorrelation values of 0.3 and 0.9 did not change the significance levels. (a) This study reported no significant difference based on a mixed analysis of variance, but based on the SMDs from the posttest and follow-up, the difference was significant.

3.5. Pre-posttest Improvement in Usual Care

Two studies did not have a TAU control,^{40,41} and three studies did not report sufficient information for

calculating pre-post change scores.⁴²⁻⁴⁴ The pooled SMC from 160 effect sizes was 0.06 [-0.09, 0.21]. The total true variance was $\sigma^2_{\text{total}} = 0.18$, $I^2 = 95\%$, indicating

interestingly high variability in the control condition.

3.6. Direct Comparison of Psychotherapeutic Approaches

Seven studies reported data on nine direct contrasts between different therapeutic approaches. The results of these direct comparisons have been presented in Table 3. However, we could not find any sensible pattern among these contrasts to suggest a reliable conclusion.

4. Discussion

This study aimed to synthesize the evidence on the efficacy of psychological interventions for improving the quality of life in Iranian adults with CP. Our original estimate indicated a large effect for these interventions; this is fairly similar to previous meta-analytic estimates from Iranian trials on other CP outcomes.¹⁰⁻¹² However, we had evidence on the presence of bias; when we corrected for the bias, the estimate showed a medium effect size. No reliable evidence was found favoring one approach over another, and the efficacy was evident for patients with musculoskeletal pain and IBS. Our data suggested a slight enhancement in the treatment effect over time, but the evidence was mainly influenced by a single RCT with a large sample size and long follow-up periods.⁴⁵

The existing meta-analytic evidence from international literature suggests a small to medium effect of psychological intervention on the QoL in chronic pain patients (the *SMDs* are usually around 0.5).³⁻⁵ While our original estimate substantially departs from these estimates, our corrected estimate was relatively comparable.

Noticeably, our corrected estimate was close to the effect size from one large Iranian RCT.⁴⁵ Altogether, the efficacy of psychological interventions in Iranian CP patients is likely fairly comparable to its efficacy in America and Europe, and if there is some cultural difference, it is less than what is suggested by the previous meta-analytic estimate from our local RCTs.^{10-12,22}

4.1. Current Evidence on the Sources of Bias in Iranian CP Trials

The substantial gap between the original and corrected estimates of treatment efficacy can indicate a strong bias. While we cannot directly determine the source of bias, we can search for supporting evidence.

Regarding publication bias, we hypothesized that if such publication bias is present, we expect the effect size from theses/dissertations (or articles that are extracted from them) to be lower than journal articles. However, our data showed very similar effect sizes from both types of RCTs. Also, exploring direct evidence on publication bias suggests that compared to international literature,⁴⁶ such bias is not higher in Iranian literature.⁴⁷ Therefore, it cannot explain why Iranian trials have higher effect sizes.

Regarding the bias due to the quality of trials, in two

systematic reviews by two independent groups of researchers, the majority of Iranian CP trials were rated as having low quality.^{11,12,24} Their quality is substantially lower than international literature, especially in some aspects such as randomization bias.³ Therefore, it seems the evidence supports the possibility that the higher effect size from Iranian RCTs may be caused by the lower quality of trials.

With regard to questionable research practice and misconduct, one study suggested that misconduct (including data falsification, data fabrication, and plagiarism) is not rare in dissertations;⁴⁸ and in the current study, at least 41% were extracted from dissertations. A second piece of evidence comes from a previous meta-analysis, in which the average *SMD* from investigations conducted by master's degree researchers was more than twice the effect size from studies conducted by PhD researchers.¹⁰ This large difference is beyond what is expected from publication bias or study quality. Finally, some features in our research community can elevate the frequency of such behaviors. A notable example is the low rate of article retraction. Our search for Persian retracted papers in Google Scholar retrieved only nine papers in all disciplines. This can indicate the lack of scrutiny for detecting such malpractice, which in turn can elevate such behaviors, as the risk of exposure is minimal. Also, our personal experience from students is that they sense an unwritten obligation to report significant results; this is usually observable when we are asked for statistical consult.

Finally, the difference between average Iranian and non-Iranian effect size is not limited to the topic of psychotherapy for CP. A similar pattern is observable in other topics, such as the efficacy of exercise on quality of life in multiple sclerosis.^{49,50} This further supports the notion that the difference between the estimates is not all genuine; local evidence bias plays a role.

4.2. The Heterogeneity among Trials

Besides moderation analysis, which assesses potential sources of heterogeneity, the multilevel model allowed us to decompose the true heterogeneity across within- and between-study levels. It suggested that the variability is mainly related to the between-study variance, and the within-study variance was minimal, regardless of its source (i.e., intervention type, measurement tool, and follow-up period). Therefore, exploring other sources of variability, such as therapists' expertise and treatment fidelity,⁵¹ may be more fruitful.

Our results on the effect of the intervention type showed substantially lower *SMD* for multidisciplinary programs, which is surprising. However, only two RCTs used such interventions, and they were the largest RCTs we have. Therefore, we highly suspect that the difference between these intervention types is similar to the

difference between the local and international evidence, especially as the corrected estimate was close to the *SMD* from these two trials. These results, along with the results from the direct comparisons, suggest no reliable preference among different therapeutic approaches.

5. Conclusion

Our results support the use of psychological interventions for improving quality of life and reducing disability in Iranian adults with CP. We observed strong bias in the observed effect sizes, with current evidence holding the low quality of trials and questionable research practice as the main source of bias. While publication bias is another possible source of bias, the supporting evidence is weak. The bias-corrected estimate suggested a moderate effect for these interventions, fairly close to the estimates from international evidence. In our situation, this corrected estimate seems to be our best guess, especially as it is supported by the estimate from a large RCT.^{45,52,53}

5.1. Limitations and Future Directions

Due to the lack of information, we did not include treatment fidelity in our analyses. This is an important limitation, especially as fidelity is likely an important aspect of heterogeneity. Another limitation is the lack of assessment for risk of bias. In the Methods section, we have explained that in our situation, such an assessment is likely of little use.

This study has several implications for future RCTs on this topic. First, for power calculation, it is probably better to assume an *SMD* of around .4–.45 as the predicted effect size. Second, enhancing the quality of trials is vital for the further development of reliable local evidence. Third, treatment fidelity and therapist expertise are two important yet neglected aspects of our literature. Finally, we need more rigorous examinations of RCTs in our local journals; we suggest that each submitted study be scrutinized for evidence on research malpractice.

Author Contributions

ZA designed the study and wrote the protocol, collaborated with the data collection, conducted the statistical analysis, interpreted the results, and wrote the manuscript. ZSH collaborated with the data collection. FA collaborated with data collection. MF collaborated with the design and provided consult. All the authors approved the final version of the manuscript for submission.

Conflict of Interest Disclosures

All authors declared that they have no conflict of interest.

Ethical Approval

Not applicable.

Funding/Support

None.

Research Highlights

What Is Already Known?

- International literature suggests a small to medium effect size for psychotherapy for CP.
- Iranian literature suggests a large effect size for psychotherapy for CP.
- The difference between the Iranian and international estimates can be genuine, or it can be caused by local evidence bias.

What Does This Study Add?

- The difference does not seem genuine, as our bias-corrected estimate is fairly comparable to the international estimates.
- Sufficient evidence indicates notable bias in our randomized trials on the efficacy of psychotherapy for CP.
- Current evidence holds low quality of trials and/or questionable research practice as the main sources of bias in our local literature.

References

1. Jensen MP, Turk DC. Contributions of psychology to the understanding and treatment of people with chronic pain: why it matters to ALL psychologists. *Am Psychol.* 2014;69(2): 105-18. doi:10.1037/a0035641
2. Jensen MP. Psychosocial approaches to pain management: an organizational framework. *PAIN®.* 2011;152(4):717-25. doi:10.1016/j.pain.2010.09.002
3. Williams AC de C, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. *Cochrane Database Syst Rev.* 2012;(11): CD007407. doi:10.1002/14651858.cd007407.pub3
4. Veehof MM, Trompetter HR, Bohlmeijer ET, Schreurs KMG. Acceptance- and mindfulness-based interventions for the treatment of chronic pain: a meta-analytic review. *Cogn Behav Ther.* 2016;45(1):5-31. doi:10.1080/16506073.2015.1098724
5. Gandy M, Pang ST, Scott AJ, Heriseanu AI, Bisby MA, Dudeney J, et al. Internet-delivered cognitive and behavioural based interventions for adults with chronic pain: a systematic review and meta-analysis of randomized controlled trials. *Pain.* 2022;163(10):e1041-53. doi:10.1097/j.pain.0000000000002606
6. Holvast F, Massoudi B, Oude Voshaar RC, Verhaak PF. Non-pharmacological treatment for depressed older patients in primary care: A systematic review and meta-analysis. *PloS One.* 2017;12(9):e0184666. doi:10.1371/journal.pone.0184666
7. Pillay T, van Zyl HA, Blackbeard D. Chronic pain perception and cultural experience. *Procedia - Soc Behav Sci.* 2014; 113:151-60. doi:10.1016/j.sbspro.2014.01.022
8. Koç V, Kafa G. Cross-cultural research on psychotherapy: The need for a change. *J Cross Cult Psychol.* 2019;50(1):100-15. doi:10.1177/0022022118806577
9. Li S, Xi Z, Barnett P, Saunders R, Shafran R, Pilling S. Efficacy of culturally adapted interventions for common mental disorders in people of Chinese descent: a systematic review and meta-analysis. *Lancet Psychiatry.* 2023;10(6):426-40. doi:10.1016/S2215-0366(23)00118-9
10. Towhidi A, Firoozi M, Jandaghi G. Meta-analysis of psychological intervention for chronic pain: Challenges and Strategies for research quality improvement. *Anesthesiol Pain.* 2019;10(3):91-104.
11. Jandaghi G, Firoozi M, Zia-Tohidi A. Psychological interventions for depression and anxiety: A systematic review and meta-analysis of Iranian chronic pain trials. *Heal Promot Perspect.* 2020;10(3):180-91. doi:10.34172%2Fhpp.2020.31
12. Jandaghi G, Zia-Tohidi A, Firoozi M. Psychological interventions for irritable bowel syndrome: A meta-analysis of Iranian randomized trials. *Arch Iran Med.* 2021;24(6):496-504. doi:10.34172/aim.2021.71
13. Vickers A, Goyal N, Harland R, Rees R. Do certain countries

- produce only positive results? A systematic review of controlled trials. *Control Clin Trials*. 1998;19(2):159-66. doi:10.1016/S0197-2456(97)00150-5
14. Cramer H, Lauche R, Langhorst J, Dobos G. Are Indian yoga trials more likely to be positive than those from other countries? A systematic review of randomized controlled trials. *Contemp Clin Trials*. 2015;41:269-72. doi:10.1016/j.cct.2015.02.005
15. Zhang D, Freemantle N, Cheng KK. Are randomized trials conducted in China or India biased? A comparative empirical analysis. *J Clin Epidemiol*. 2011;64(1):90-5. doi:10.1016/j.jclinepi.2010.02.010
16. Pan Z, Trikalinos TA, Kavvoura FK, Lau J, Ioannidis JPA. Local literature bias in genetic epidemiology: An empirical evaluation of the Chinese literature. *PLoS Med*. 2005;2(12):1309-17. doi:10.1371/journal.pmed.0020334
17. Panagiotou OA, Contopoulos-Ioannidis DG, Ioannidis JPA. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. *BMJ*. 2013;346:f707. doi:10.1136/bmj.f707
18. Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. *BMJ*. 2008;336(7644):601-5. doi:10.1136/bmj.39465.451748.AD
19. Xie Y, Wang K, Kong Y. Prevalence of Research Misconduct and Questionable Research Practices: A Systematic Review and Meta-Analysis. *Sci Eng Ethics*. 2021;27(4):41. doi:10.1007/s11948-021-00314-9
20. Nakagawa S, Lagisz M, Jennions MD, Koricheva J, Noble DWA, Parker TH, et al. Methods for testing publication bias in ecological and evolutionary meta-analyses. *Methods Ecol Evol*. 2022;13(1):4-21. doi:10.1111/2041-210X.13724
21. Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ*. 2011;343:d4002. doi:10.1136/bmj.d4002
22. Vesal M, Neshatdust HT. Meta-analysis of psychological intervention's effectiveness on reduction of pain intensity among patients with chronic pain. *J Anesthesiol Pain*. 2019;10(3):21-38.
23. [Reference deleted for blind review]
24. Faizi F, Tavallaee A, Rahimi A, Saburi A, Saghafeinia M. Quality assessment of randomized control trials applied psychotherapy for chronic pains in iran: a systematic review of domestic trials. *Iran Red Crescent Med J*. 2014;16(9):e15312. doi:10.5812/ircmj.15312
25. Hedges L V., Tipton E, Zeinullahi R, Diaz KG. Effect sizes in ANCOVA and difference-in-differences designs. *Br J Math Stat Psychol*. 2023;76(2):259-82. doi:10.1111/bmsp.12296
26. Borenstein M, Hedges L V. Effect Sizes for Meta-Analysis. In: Cooper H, Hedges L V, Valentine JC, editors. *The Handbook of Research Synthesis and Meta-Analysis*. 3rd ed. New York: The Russell Sage Foundation; 2019. pp. 107-244.
27. Langan D, Higgins JP, Jackson D, Bowden J, Veroniki AA, Kontopantelis E, et al. A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses. *Res Synth Methods*. 2019;10(1):83-98. doi:10.1002/jrsm.1316
28. Viechtbauer W. Confidence intervals for the amount of heterogeneity in meta-analysis. *Stat Med*. 2007;26(1):37-52. doi:10.1002/sim.2514
29. Hedges LV, Tipton E, Johnson MC. Robust variance estimation in meta-regression with dependent effect size estimates. *Res Synth Methods*. 2010;1(1):39-65. doi:10.1002/jrsm.5
30. Rodgers MA, Pustejovsky JE. Evaluating meta-analytic methods to detect selective reporting in the presence of dependent effect sizes. *Psychol Methods*. 2021;26(2):141-60. doi:10.1037/met0000300
31. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. *J Stat Softw*. 2010;36(3):1-48. doi:10.18637/jss.v036.i03
32. Del Re AC. compute.es: Compute Effect Sizes. R Package. 2013.
33. Mahdipoor M, Zargar Y, Davoodi I. Comparing the efficacy of combining psychological-medical therapy and medical therapy on mental health, improving quality of life, and reducing symptoms in patients with irritable bowel syndrome in Ahvaz. In: *Fourth international psychosomatic congress*; 2012.
34. Jafari R, Shalchi B. The efficacy of mindfulness-based cognitive-behavioral therapy on psychological wellbeing and quality of life in patients with chronic pain disorder. In: *The 7th Scientific & Research Conference on the Development and Promotion of Educational Sciences & Psychology in Iran*, 2020.
35. Sadeghi M, Moradi Z. Effectiveness of Acceptance- and Commitment-Based Therapy on Pain Perception and Functional Disability in Women with Rheumatoid Arthritis. *Sci J Sch Public Heal Inst Public Heal Res*. 2020;18(2):199-214.
36. Shafiee Fard Y, Besharat MA, Bahrami Ehsam H, Taheri A. Effectiveness of Group Cognitive – Behavioral Therapy on Quality of Life, Depression, Anxiety and Stress among Patients with chronic pain. *Appl Psychol Res Q*. 2015;6(1):209-24.
37. Pourmohseni-Koluri F, Eslami F. The effectiveness of group cognitive therapy based on mindfulness on mental health and quality of life of patients with irritable bowel syndrome. *Health Psychol*. 2017;5(20):48-67.
38. Esmailpoor B, Aleyasin SA. Effectiveness of emotional intelligence training on anxiety and quality of life for patients with irritable bowel syndrome. In: *3rd international conference on psychology, educational sciences, and lifestyle with international approach*; 2017.
39. Kaviani H, Mousavi AS. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). *Tehran Univ Med J*. 2008;65(2):136-40.
40. Haghayegh SA. Efficacy of Dialectical Behavioral Therapy and Emotion Focused Therapy on emotional memory and psychological indexes of IBS patients. *University of Isfahan*; 2012.
41. Naddafnia L, Ebrahimi A, Neshatdust HT, Talebi H. Comparison of Effectiveness of Cognitive Behavioral Therapy and Spiritual Therapy on Symptoms Intensity, Quality of Life, in Patients with Irritable Bowel Syndrome. *J Res Behav Sci*. 2019;17(2):291-302. doi:10.52547/rbs.17.2.291
42. GhotbnejhadBahreAsmani U, Ahadi H, Hatami H, SaramiForoushani G. Comparison of the Effectiveness of group positive psychotherapy and group psychodrama on spiritual attitude, distress tolerance, and quality of life in women with chronic pain. *J Anesthesiol pain*. 2019;9(4):51-65.
43. Salarian B, ShomaliOskoueie A, ArefNazari M. The Effect of Mindfulness on Quality of Life and Chronic Pain Management. *Med J Mashhad Univ Med Sci*. 2020;62:497-506.
44. Irandoost F, Neshatdoost HT, Nadi MA. The effectiveness of Acceptance and Commitment Therapy (ACT) on quality of life of women with chronic low back pain. *Int J Behav Sci*. 2014;8(1):89-96.
45. Tavafian SS, Jamshidi AR, Mohammad K. Treatment of low back pain: Second extended follow up of an original trial (NCT00600197) comparing a multidisciplinary group-based rehabilitation program with oral drug treatment alone up to 30 months. *Int J Rheum Dis*. 2017;20(12):1910-6. doi:10.1111/1756-185X.12540
46. Dwan K, Gamble C, Williamson PR, Kirkham JJ, Reporting Bias Group. Systematic review of the empirical evidence of study publication bias and outcome reporting bias—an updated review. *PLoS One*. 2013;8(7):e66844. doi:10.1371/journal.pone.0066844
47. Navabi N, Shahravan A, Yazdi SM, Montajab F. Probability of Publication Bias in Published Articles Resulting from Dental Dissertations of Medical Sciences Universities in Iran. *Pesqui Bras Odontopediatria Clin Integr*. 2020;19:e4756. doi:10.4034/PBOCI.2019.191.104
48. Khadem-Rezaian M, Dadgarmoghaddam M. Research misconduct: A report from a developing country. *Iran J Public Health*. 2017;46(10):1374-8.
49. Afkar A, Ashouri A, Rahmani M, Emami Sigaroudi A. Effect of exercise therapy on quality of life of patients with multiple sclerosis in Iran: a systematic review and meta-analysis. *Neurol Sci*. 2017;38(11):1901-11. doi:10.1007/s10072-017-3047-x
50. Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: A meta-analysis. *Mult Scler*. 2008;14(1):129-35. doi:10.1177/1352458507080464
51. Edmond SN, Turk DC, Williams DA, Kerns RD. Considerations of trial design and conduct in behavioral interventions for the management of chronic pain in adults. *Pain Reports*. 2019;4(3):1-10. doi:10.1097%2FPR9.0000000000000655

52. Tavafian SS, Jamshidi AR, Mohammad K. Treatment of chronic low back pain: a randomized clinical trial comparing multidisciplinary group-based rehabilitation program and oral drug treatment with oral drug treatment alone. *Clin J Pain*. 2011;27(9):811-8. doi:10.1097/ajp.0b013e31821e7930
53. Tavafian SS, Jamshidi AR, Shay B. Treatment of low back pain: First extended follow up of an original trial (NCT00600197) comparing a multidisciplinary group-based rehabilitation program with oral drug treatment alone up to 24 months. *Int J Rheum Dis*. 2017;20(12):1902-9. doi:10.1111/1756-185X.12468
54. Tabatabaee Shahrabad A. The Effectiveness of Metacognitive Therapy on Anxiety, Depression and Quality of life of Patients with Irritable Bowel Syndrome (Thesis) [Internet]. Ferdowsi University of Mashhad; 2014. <https://ganj.irandoc.ac.ir/#/articles/5eba7c222a8b3e725e0f584ec4e485fb> [Accessed January 5, 2022]
55. Zomorodi S, Rasoulzadeh Tabataba'i SK. Comparison of Effectiveness of Cognitive-Behavioral Therapy and Mindfulness-Based Therapy in Improving quality of life in patients with irritable bowel syndrome. *Clin Psychol Stud*. 2013;4(13):63-88.
56. Sadeghi Mazidi S. The Effect of Training on coping with stress and Emotion Regulation on Life Style and pain in Chronic Low Back Pain [thesis]. Payame Noor University-Tehran Jonoub; 2015.
57. Tavakoli H, Akbari B, Salari A. Group based acceptance and commitment therapy on quality of life and psychological flexibility in patients with non-cardiac chest pain. *Middle East J Disabil Stud*. 2019;9:108.
58. Firoozi M, Haghdoust A. The Effectiveness CBT Based on Positive Thinking Using Computer Program and Virtual Social Networks on Improving Quality of Life in Patients with Chronic Low Back Pain. *J Anesthesiol pain*. 2020; 11(3):66-76.
59. Rezaie F. [A comparison of the effectiveness of emotion focused cognitive behavioral therapy, and schema therapy on pain, pain catastrophizing, emotion regulation and quality of life in rheumatoid arthritis patients (PHD thesis) (Persian)] [Internet]. 2014. <https://ganj.irandoc.ac.ir/#/articles/9d43d8eb2ee06a013a3e031754648b3b> [Accessed January 5, 2022]
60. Masumian S. The Effect of Mindfulness-Based Stress Reduction (MBSR) on Decreasing Depression, increasing Quality of Life and self-efficacy of the Chronic Low back Pain Patients (CLBP) [Internet]. Allameh Tabataba'i university; 2013. <https://ganj.irandoc.ac.ir/#/articles/a36bb03bf27a84efa275cd81e9261aba> [Accessed January 5, 2022]
61. Haghayegh S, Kalantari M, Molavi H, Talebi M. Efficacy of cognitive-behavior therapy on the quality of life of patients suffering from irritable bowel syndrome with predominant pain and diarrhea types. *J Psychol*. 2010;14:195-110.
62. Abazari N. the effectiveness of hypnotherapy with physiotherapy on pain intensity, psychological distress, and functional disability in patient with chronic non-specific low back pain. University of Semnan; 2016.
63. Parhizgar M, Moradi Manesh F, Serajkhorrani N, Ehteshamzadeh P. The Effectiveness of mindfulness integrated cognitive behavior therapy on pain syndrome, quality of life relative with health anxiety. *Thoughts and Behavior in Clinical Psychology*. 2019;14(54):37-46.
64. Farokhzadian AA, Ahmadian F, Andalib L. The Effectiveness of Acceptance and Commitment Therapy on the Severity of Symptoms and Quality of Life in Soldiers with Irritable Bowel Syndrome. *J Mil Med*. 2019;21(1):44-52.
65. Kamkar A. The Effectiveness of group Cognitive – Behavioral Stress Management on physical Symptoms of Patients with Irritable Bowel Syndrome with and without comorbidity of anxiety and depression and on increase of their quality of life (Thesis) [Internet]. Allameh Tabataba'i University; 2011. <https://ganj.irandoc.ac.ir/#/articles/955fef8788af646c279def0e083d54e3> [Accessed January 5, 2022]
66. Mohamadi J, Azizi A. Dialectical Behavior Therapy Group on the Perception of the Disease and Quality of Life of Patients with Irritable Bowel Syndrome. *Sci J Ilam Univ Med Sci*. 2017;25(2):18-26.
67. Azizi A. Mindfulness Efficacy on the Perception of the Disease and the Quality of Life of Patients with Irritable Bowel Syndrome. *J Ilam Univ Med Sci*. 2018;25(6):1-9. doi:10.29252/sjimu.25.6.1
68. Dabbaghi Zarif S. Effectiveness of mindfulness based stress reduction (MBSR) on mental health and quality of life in Irritable Bowel Syndrome (IBS) cases. Payam Noor University; 2015.
69. Solati-Dehkordi K. A comprehensive study of cognitive-behavioral therapy, life style training, relaxation and medication therapies on quality of life, psychological symptoms, severity and frequency of symptoms IBS-d patients (Thesis) [Internet]. University of Isfahan; 2009. <https://ganj.irandoc.ac.ir/#/articles/e3e319fcd99ff7be8095245afb35258> [Accessed January 5, 2022]
70. Pashing S, Khosh Lahjeh Sedgh A. Comparison of effectiveness of acceptance commitment therapy and metacognitive therapy on reducing symptoms, psychological capital and quality of life of patients suffering from irritable bowel syndrome. *Med Sci J Islam Azad Univ*. 2019;29(2):181-90. doi:10.29252/iau.29.2.181
71. Kheir-Abadi G, Bagherian R, Nemati K, Daghighzadeh H, Maracy MR, Gholamrezaei A. The effectiveness of coping strategies training on symptom severity, quality of life and psychological symptoms among patients with irritable bowel syndrome. *J Isfahan Med Sch*. 2010;28(110):1-11.
72. Shojaei S, Tavafian SS, Jamshidi AR, Wagner J. A multidisciplinary workplace intervention for chronic low back pain among nursing assistants in Iran. *Asian Spine J*. 2017;11(3):419-26. doi:10.4184/asj.2017.11.3.419
73. Chamani Ghalandary R, Ardalan MA, Dokaneifard F, Chamani S, Ghamchili A, Razei H, et al. The effectiveness of cognitive-behavioral therapy on the general health and quality of life of patients with irritable bowel syndrome. *Nurse Physician Within War*. 2019;23(7):5-10.
74. Anvari MH, Ebrahimi A, Neshatdoost HT, Afshar H, Abedi A. The effectiveness of group-based acceptance and commitment therapy on pain-related anxiety, acceptance of pain and pain intensity in patients with chronic pain. *J Isfahan Med Sch*. 2014;32(295):1156-65.
75. Vakili N. effectiveness of group cognitive behavior therapy on depression, quality of life of patients with low back pain (thesis) [Internet]. university of Isfahan; 2009. <https://ganj.irandoc.ac.ir/#/articles/b2b7098cf66f60dc929fe74ef784ab4a> [Accessed January 5, 2022]
76. Rezaeian M, Ebrahimi A, Zargham M. The effect of acceptance and commitment therapy on catastrophic and disabling pain in chronic pelvic pain in Females. *Res Cogn Behav Sci*. 2015;4(2):17-30.
77. Dadollahi Sarab R. The effect of mindfulness-based stress reduction program (MBSR) on reducing symptoms of irritable bowel syndrome (IBS). Shahid Bahonar University of Kerman; 2016. <https://ganj.irandoc.ac.ir/#/articles/36a6500447f15bfb88f76f6b04c83d67> [Accessed January 5, 2022]
78. Fouladi N, Mohammadkhani S, Shahidi E, Ebrahimi Daryani N. The Effectiveness of Cognitive Behavioral Therapy in Improving and Promoting of Physical and Mental Health of Patients with Irritable Bowel Syndrome. *J Heal Educ Heal Promot*. 2018;6(3):312-23. doi:10.30699/acadpub.ijhehp.6.3.312
79. Mansoobi M. The efficacy of acceptance and commitment therapy on quality of life and emotion regulation in patients with chronic low back pain. In: Fourth National Conference on Psychology and Behavioral Sciences, Payame Noor University; 2020.
80. Vakili T, Hasanzadeh R. The effectiveness of group reality therapy on quality of life among patients with irritable bowel syndrome. In: 3rd international conference on psychology, counseling, and education; 2020.
81. Soltanian G, Najafi M, Rafienia P, Mirfeizi Z. The effectiveness of cognitive-behavioral group therapy on quality of life in patients with rheumatoid arthritis. *Pajoohandeh J*. 2016;21(3):122-9.
82. Ayoughi Rahnema V, Zareipoor M, Ghorbanalipour M. Effect of Stress Inoculation Training on Quality of Life of Patients with Rheumatoid arthritis: A Clinical Trial. *Iran J Orthop Surg*. 2019;17(2):70-7. doi:10.22034/ijos.2020.121391
83. Boloorsaz Mashhadi H, Aghaei M, Mohammadkhani M, Mahdavi A. Examining the Effect of Teaching Islamic-based Coping Strategies on Indicators of Chronic Pain and Quality of Life among Women with Fibromyalgia. *J Res Reli Heal*. 2017;3(4):48-65.